## 3<sup>rd</sup> Annual

# **HEART IN DIABETES**

Where the Heart, Kidney and Diabetes Meet in Clinical Practice

**EARN CME ACCME CREDITS** 24.75



Jointly Provided By: MEEF











Dear Friends & Colleagues,

We would like to invite you to join us for the 3rd Annual Heart in Diabetes (HiD) Medical Conference. Following the incredible success of the initial two HiD meetings, along with encouragement from participants and combined with overabundance of new data, planning for the 3rd Heart in Diabetes is underway. The Conference will be held July 12-14, 2019, at the Loews Philadelphia Hotel (1200 Market St, Philadelphia, PA 19107).

This CME program is a unique medical conference designed to evaluate state-of-the-art clinical research outcomes on heart and kidney disease in diabetes and its implications for clinical practice. HiD will bring together world-renowned clinical leaders in diabetes and CVD, CKD and the liver to develop a multi-disciplinary, comprehensive understanding of the impact of new clinical science on the management of cardiometabolic conditions. The goal is to help cardiologists, endocrinologists, lipidologists, nephrologists, hepatologists and Primary Care Experts align their goals and management approaches to provide best practices for high-risk patients.

Recent trials have demonstrated a cardiovascular benefit from agents that control glycemia, lipids, blood pressure, and inflammation in people with diabetes. However, among practicing professionals, including experts in the field, there is a gap in understanding the implications of these new developments and their impact on disease management.

The meeting provides up-to-date clinical science of the Heart in Diabetes by providing multidisciplinary outcome data and its implications for practice by evaluating data from the cardiology, endocrine/diabetes, and kidney points of view. Sessions will cover data and management of lipids, glucose, coronary syndromes, congestive heart failure, the kidney, coagulation, arrhythmia, other related conditions, while evaluating the relevance of society guidelines. The meeting will promote discussions through panels and debates and, for the first time this year, HiD will showcase abstracts which will be published in Clinical Cardiology.

If you are a cardiologist, endocrinologist, nephrologist, diabetologist, lipidologist, internist, or a clinician with an interest in the science of the Heart in Diabetes, this meeting is for you! We personally invite you to join us in this exciting endeavor. Please also consider submitting an abstract.

Please register today! Do not hesitate to contact us with any questions. We look forward to seeing you in Philadelphia in July!

Thank you,



Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE



Mikhail N. Kosiborod, MD, FACC, FAHA

## **Heart in Diabetes (HiD) Scientific Committee**

**Yehuda Handelsman, MD** *Chair* Tarzana, California

**Mikhail N. Kosiborod, MD** *Chair* Kansas City, Missouri

**Deepak L. Bhatt, MD**Boston, Massachusetts

**Zachary T. Bloomgarden, MD** New York, New York

Matthew J. Budoff, MD Los Angeles, California

**Javed Butler, MD** Oxford, Mississippi

David Cherney, PhD, MD Toronto, Canada

**Robert J. Chilton, DO** San Antonio, Texas

Mark E. Cooper, AO, PhD Melbourne, Australia Michael H. Davidson, MD Chicago, Illinois

**Ralph A. DeFronzo, MD** San Antonio, Texas

**Stefano Del Prato, MD** Pisa, Italy

**Daniel Einhorn, MD** San Diego, California

Michael E. Farkouh, MD Toronto, Canada

**Sergio Fazio, MD, PhD**Portland, Oregon

Vivian A. Fonseca, MD New Orleans, Louisiana

Alan J. Garber, MD, PhD

Peter J. Grant, MD Leeds, United Kingdom

Houston, Texas

**George Grunberger, MD** Bloomfield Hills, Michigan

Mansoor Husain, MD Toronto, Canada

**Silvio E. Inzucchi, MD** New Haven, Connecticut

**Paul S. Jellinger, MD** Hollywood, Florida

Mark Kearney, MD Leeds, United Kingdom

Lawrence A. Leiter, MDCM Toronto, Canada

Norman E. Lepor, MD Los Angeles, California

Derek LeRoith, MD, PhD New York, New York

Christos S. Mantzoros, MD, PhD Boston, Massachusetts **Nikolaus Marx, MD** Aachen, Germany

Darren K. McGuire, MD Dallas, Texas

**Christian W. Mende, MD** San Diego, California

Richard E. Pratley, MD Orlando, Florida

Kausik Ray, MD, MPhil London, United Kingdom

Peter Reaven, MD Phoenix, Arizona

**Benjamin M. Scirica, MD** Boston, Massachusetts

**Laurence Sperling, MD** Atlanta, Georgia

Matthew R. Weir, MD Baltimore, Maryland

#### **PROGRAM DESCRIPTION:**

This CME conference is a unique medical meeting that brings world-renowned clinical leaders in diabetes and cardiovascular disease together with practicing clinicians to improve the care of patients at high risk of cardiovascular, metabolic, and kidney diseases. At HiD, experts and clinicians explore the state-of-the-art in clinical science of the Heart in Diabetes, with in-depth examination of the latest evidence from clinical trials on lipid disorders, glucose abnormalities, congestive heart failure, atherosclerosis, vascular disease, kidney disease, coagulation abnormalities, arrhythmia, and related conditions to understand their implications on practice.

## **PROGRAM OBJECTIVES:** Upon completion of this meeting, participants should be able to:

- Provide comprehensive management of diabetes, addressing obesity, hypertension, dyslipidemia, and hyperglycemia
- Evaluate the relationship between diabetes, the heart, and the kidneythe cardiorenal syndrome
- Evaluate the extent of vascular disease in diabetes and cardiometabolic conditions
- Provide management recommendations of cardiovascular conditions, in DM and Obesity
- Evaluate the impact on clinical practice of new cardiovascular outcome trials in patients with diabetes
- Discuss the role of incretins in the management of obesity, diabetes, and their complications
- Compare and contrast changes in lipid management guidelines: ACC/ AHA vs AACE
- Evaluate the evidence supporting the use of SGLT2 inhibitors and GLP1-ras to reduce cardiovascular mortality in patients with T2D
- Describe the mechanism of action of SGLT2 inhibitors, GLP1-ras and EPA in reducing adverse cardiovascular outcomes

- Evaluate the extent of CVD and CKD in diabetes and obesity
- Describe the role of PCSK9i in lipid elevations and impact on CVD, addressing the role in women
- Explain the relationship between diabetes, obesity, and congestive heart failure- focus on HFpEF and potential management
- Discuss the role of SGLT2 inhibitors in the management of diabetes and obesity addressing their complications
- Recognize the role of the liver, fatty liver disease, and NASH in the development of CVD in diabetes
- Describe changes in the epidemiology of cardiovascular and kidney disease in people with diabetes and obesity
- Appropriately diagnose and treat hypercoagulation and thrombosis as consequences of insulin resistance, inflammation, and diabetes
- Evaluate the proper administration of antiplatelet and anticoagulation agents in the management of the high-risk patient
- Acquire tools to understand how new agents impact CVD in DM to be able to consider SGLT2i vs GLP1-ras vs PCSK9i vs EPA in people with DM and established CVD.

#### **TARGET AUDIENCE**

Cardiologists, endocrinologists, nephrologists, diabetologists, lipidologists, internists, family clinicians, and other professionals who are interested in the Heart in Diabetes.

#### HEART IN DIABETES PROGRAM COMMITTEE

Yehuda Handelsman, MD, Chair • Mikhail N. Kosiborod, MD, Chair • Deepak Bhatt, MD • Zachary T. Bloomgarden, MD • Matthew J. Budoff, MD • Javed Butler, MD • David Cherney, MD, PhD • Robert J. Chilton, DO • Michael H. Davidson, MD • Ralph A. DeFronzo, MD • Daniel Einhorn, MD • Michael E. Farkouh, MD • Sergio Fazio, MD, PhD • Vivian A. Fonseca, MD • Alan J. Garber, MD, PhD • Peter J. Grant, MD • George Grunberger, MD • Silvio E. Inzucchi, MD • Lawrence A. Leiter, MDCM • Norman E. Lepor, MD • Derek LeRoith, MD, PhD • Christos S. Mantzoros, MD, DSc, PhD • Nikolaus Marx, MD • Darren K. McGuire, MD • Kausik Ray, MD • Matthew R. Weir, MD • Renee S. Asp, BS

The HiD Scientific Committee Gratefully Acknowledges the Unrestricted Educational Grants of Premier Educator: ASTRAZENECA • Leader Educator: MERCK Major Educator: NOVO NORDISK • Educator: AMARIN • BI/LILLY

10:15AM - 10:45AM REFRESHMENT BREAK AT EXHIBIT HALL

10.00	Do Dodganation	
10:00am 1:00pm — 2:00pm	Pre-Registration EXHIBIT HALL OPEN/WELCOME	
2:00pm — 2:10pm	Welcome & Introduction  Yehuda Handelsman, MD • Mikhail N.	
2:10pm — 2:20pm	Pre-CME Questions	mode Handosman, ind Hinkilan II. Rosidord, ind
SESSION 1	DIABETES & ATHEROSCLEROSIS Chairs: Norman E. Lepor, MD • Silvio E. Inzucchi, MD	
2:20pm — 2:40pm 2:40pm — 3:00pm 3:00pm — 3:20pm 3:20pm — 3:35pm	Is Inflammation Causal for Both Atherosclerotic and Non-Atherosclerotic CV Events in Diabetes? Effects of Glucose Variation on Vascular Disease Outcomes in ACCORD and the VADT Coronary Atherosclerosis in DM Q+A Panel Discussion	Michael H. Davidson, MD Peter Reaven, MD Matthew J. Budoff, MD
3:35PM - 4:10PM KEY NOTE	AWARD PRESENTATION "Luminary in Cardiometabolic Medicine"  Presented by: Michael E. Farkouh, MD • Yehuda Handelsman, MD • Mikhail N. Kosiborod, MD  Subclinical Arterial Disease: Imaging, Genetics, and Behavior	Valentin Fuster, MD, PhD
4:10pm — 4:30pm	Big Data and Health	Michael Snyder, PhD
4:30PM - 5:00PM	REFRESHMENT BREAK AT EXHIBIT HALL	
SESSION 2	HEART IN DIABETES WITH CIRCULATION Chair: Darren K. McGuire, MD, MHSc	
5:00pm - 5:10pm 5:10pm - 5:25pm 5:25pm - 5:40pm 5:40pm - 5:55pm 5:55pm - 6:10pm 6:10pm - 6:25pm 6:25pm - 6:30pm	Introduction Effects of SGLT2i on Hemoglobin/Hematocrit Metformin in Youth with Type 1 Diabetes Mellitus Once-Weekly Exenatide in Patients With Pre-Existing Cardiovascular Disease Effects of Ezetimibe in Patients with Diabetes: Results from IMPROVE-IT Heart Failure Considerations of Antihyperglycemic Therapies Wrap-up/Ask the Editor	Darren K. McGuire, MD, MHSc Shinichi Goto, MD, PhD Jane E.B. Reusch, MD Robert J. Mentz, MD Robert P. Giugliano, MD Muthiah Vaduganathan, MD, MPH Darren K. McGuire, MD, MHSc
SESSION 3	CARDIABETES — A SPECIALTY? Chairs: Mikhail N. Kosiborod, MD • Robert J. Chilton, DO	
6:30pm — 6:50pm 6:50pm — 7:10pm 7:10pm — 7:25pm 7:25pm — 7:30pm	Cardiometabolic Medicine: Time for a New Subspeciality Expert in Cardiabetes Should be Preventive Cardiologist Q+A Panel Discussion Post CME Questions	Robert H. Eckel, MD Sergio Fazio, MD, PhD
7:30PM - 8:30PM	WELCOME & POSTERS RECEPTION AT EXHIBIT HALL	
		SATURDAY JULY 13, 2019
7:00AM - 8:00AM	REGISTRATION • CONTINENTAL BREAKFAST	
8:00am — 8:10am	Pre-CME Questions	
SESSION 4	HEART IN DIABETES WITH JACC Chairs: Michael E. Farkouh, MD ● Robert S. Rosenson, MD	
8:10am — 8:20am 8:20am — 8:35am 8:35am — 8:50am 8:50am — 9:05am 9:05am — 9:20am 9:20am — 9:35am 9:35am — 9:40am	Introduction The Influence of CKD on Outcomes in Patients with DM and CAD Undergoing Coronary Revascular Hypoglycemia and Elevated Troponin in Patients with DM and Coronary Artery Disease Heart Failure with Preserved Ejection Fraction and Diabetes Cardiovascular and Limb Outcomes in Patients with DM and Peripheral Artery Disease The Evolving Future of PCSK9 Inhibitors in Patients with Diabetes Wrap-up/Ask the Editor	Michael E. Farkouh, MD rization Mandeep S. Sidhu, MD Paulo C. Rezende, MD, PhD David Fitchett, MD Cecilia C. Low Wang, MD Robert S. Rosenson, MD Michael E. Farkouh, MD
SESSION 5	MANAGEMENT & PREVENTION OF ASCVD Chairs: Daniel Einhorn, MD • Laurence Sperling, MD	
9:40am — 10:00am 10:00am — 10:15am	Diabetes & Thrombotic Risk: From Mechanisms and Therapeutics to Guidelines Clonal Hematopoiesis of Indeterminate Potential	Peter J. Grant, MD Robert J. Chilton, DO
1015444 1045444	DEFECTION TO THE PROPERTY OF T	

## SATURDAY JULY 13, 2019 (cont.)

POINT-COUNTER-POINT: OPTIMAL INITIAL APPROACH TO THE STABLE ELECTIVE PATIENT WITH DIABETES AND 2-VESSEL DISEASE					
10:45am — 11:00am 11:00am — 11:15am 11:15am — 11:30am	Medical Therapy PCI CABG	Martha Gulati, MD Michael E. Farkouh, MD Marc Ruel, MD			
11:30am — 11:45am	Q+A Panel Discussion	,			
SESSION 6	GLYCEMIA, THE HEART & THE BRAIN Chairs: Zachary T. Bloomgarden, MD • Matthew J. Budoff, MD				
11:45am — 12:05pm 12:05pm — 12:25pm 12:25pm — 12:45pm 12:45pm — 1:00pm	Epidemiologic Evidence Linking Hypoglycemia to the Heart and Brain The Impact of Postprandial Hyperglycemia - IGT on CVD Prediabetes: The Prelude to Macrovascular Complications Q+A Panel Discussion	Elizabeth Selvin, PhD Stefano Del Prato, MD Ralph A. DeFronzo, MD			
1:00PM - 2:00PM	BREAK				
SESSION 7	MODE OF ACTION Chairs: Ralph A. DeFronzo, MD ● Mansoor Husain, MD				
2:00pm — 2:20pm 2:20pm — 2:40pm 2:40pm — 3:00pm 3:00pm — 3:20pm 3:20pm — 3:35pm	Mechanisms of Hormones & Nutrition in Management of CVD & ACS in DM Impact of SGLT2i on CV Risk & Outcome in DM Impact of GLP1-ra on CV Risk & Outcome in DM Impact of EPA on CV Risk & Outcome in DM Q+A Panel Discussion	Christos S. Mantzoros, MD, PhD Subodh Verma, MD, PhD Michael Nauck, MD Eliot A. Brinton, MD			
SESSION 8	LDL & TGL IN DIABETES Chairs: Paul S. Jellinger, MD ● Sergio Fazio, MD, PhD				
3:35pm — 3:55pm 3:55pm — 4:15pm	The Lower LDL the Better The Role of PCSK9 Inhibitors in High Risk Patient Groups	Antonio Gotto Jr., MD, DPhil Pam R. Taub, MD			
4:15PM - 4:45PM	REFRESHMENT BREAK AT EXHIBIT HALL				
	GH TGL IS IMPORTANT IN THE PREVENTION & MANAGEMENT OF CVD  YES	Datas D Taila MD DLD			
4:45pm — 5:00pm 5:00pm — 5:15pm	NO	Peter P. Toth, MD, PhD Norman E. Lepor, MD			
5:15pm — 5:30pm SESSION 9	Q+A Panel Discussion PRACTICE RECOMMENDATIONS 2019				
3E33IUN 9	Chairs: George Grunberger, MD ● Peter J. Grant, MD				
5:30pm — 5:50pm 5:50pm — 6:00pm 6:00pm — 6:15pm 6:15pm — 6:35pm 6:35pm — 6:55pm 6:55pm — 7:00pm	Vivisection of the ADA-EASD Consensus Report AACE Diabetes Algorithm 2019 Update ACC DM Consensus ACC/AHA New Lipids Guidelines Q+A Panel Discussion Post CME Questions	Silvio E. Inzucchi, MD Alan J. Garber, MD, PhD Mikhail N. Kosiborod, MD Laurence Sperling, MD			

#### **CME DINNER SYMPOSIUM**

#### THE PRIMARY PREVENTION OF CHF & CKD IN DIABETES



7:30pm **Introduction & CME Questions** Yehuda Handelsman, MD • Mikhail N. Kosiborod, MD Major Complications of Diabetes: Epidemiology of CHF and CKD Maria Rosa Costanzo, MD 7:40pm Peter A. McCullough, MD 8:00pm The Fatal Connection — Diabetes, the Kidney, and the Heart: The Cardiorenal Syndrome Contemporary Approach to Preventing CHF in Diabetes: Focus on Primary Prevention Javed Butler, MD 8:20pm George L. Bakris, MD 8:40pm The Role of SGLT2 Inhibitors in the Prevention and Management of CKD in Diabetes

Panel Discussion and Q&A: Treatment of Diabetes in 2020 - Preferred Medications to Prevent Complications 9:00pm

George L. Bakris, MD • Javed Butler, MD • Mark E. Cooper, AO, PhD Maria Rosa Costanzo, MD • Peter A. McCullough, MD • Matthew R. Weir, MD

Moderators: Yehuda Handelsman, MD • Mikhail N. Kosiborod, MD

**9:20–9:30pm** Post-CME Questions/Concluding Remarks

Supported by an Educational Grant from: AstraZeneca



#### 7:00AM - 8:00AM REGISTRATION • CONTINENTAL BREAKFAST

## 7:00AM - 8:00AM ABSTRACT ORAL PRESENTATIONS

Committee: George Grunberger, MD, Chair ◆ Zachary T. Bloomgarden, MD ◆ Matthew J. Budoff, MD ◆ Michael H. Davidson, MD
Michael E. Farkouh, MD ◆ Vivian A. Fonseca ◆ Lawrence A. Leiter, MD ◆ Derek LeRoith, MD, PhD

Abstracts will be published in CLINICAL CARDIOLOGY Editor-in-Chief: A. John Camm, MD

	Abstracts will be published in <i>Clinical Cardiology</i> Editor-In-Chiet: A. John Camm, MD		١,
8:00am — 8:10am	Pre-CME Questions		
8:10AM - 8:15AM	ORAL ABSTRACT WINNERS AWARD PRESENTATION	George Grunberger, MD	
SESSION 10	ROLE OF ETHNICITY, AGE & GENDER ON CV RISK IN DM Chairs: Stefano Del Prato, MD • Christos S. Mantzoros, MD, PhD		
8:15am — 8:35am 8:35am — 8:55am 8:55am — 9:15am 9:15am — 9:30am	Impact of Age of Diagnosis, Gender and Ethnicity on CVD Risk in Diabetes State of Diabetes' Impact on Heart Disease in Colombia DM and Heart Disease in the Older Patient — The Evidence for Targets Q+A Panel Discussion	Juliana CN Chan, MD Eric Hernandez-Triana, MD Richard E. Pratley, MD	
SESSION 11	CHF, CKD & OBESITY IN DIABETES Chairs: Mark E. Cooper, AO, PhD • Deepak L. Bhatt, MD		
9:30am — 9:50am 9:50am — 10:10am	Heart Failure Outcomes in DM CVOTs — Should Secondary Endpoints Guide Clinical Care? Management of CHF in DM - Circa 2019	Javed Butler, MD Biykem Bozkurt, MD, PhD	
10:10AM - 10:25AM	REFRESHMENT BREAK		
10:25am — 10:45am 10:45am — 11:05am 11:05am — 11:20am	Obesity and Cardiorenal Failure Impact of Obesity on Liver & the Heart Q+A Panel Discussion	Matthew R. Weir, MD Samuel Klein, MD	
SESSION 12	CV RISK PREDICTION Chairs: Michael H. Davidson, MD • Christian W. Mende, MD		
11:20am — 11:35am 11:35am — 11:55am 11:55am — 12:05pm	Predicting CHF — Clinical Signs, Biomarkers or Risk Engines? Predicting the High-Risk Primary Prevention Patient - What is the Best Option in the Clinic? Q+A Panel Discussion	Vivian A. Fonseca, MD Kausik Ray, MD	
SESSION 13	DIABETES OUTCOME TRIALS - UPDATE Chairs: Kausik Ray, MD • Peter Reaven, MD		
12:05pm — 12:25pm 12:25pm — 12:50pm	CVOT Data: REDUCE-IT, ODYSSEY, REWIND, ASCEND Diabetic Kidney Disease and SGLT2i: Focus on CREDENCE Results	Deepak L. Bhatt, MD George L. Bakris, MD	
12:50PM - 1:05PM	REFRESHMENT BREAK		
1:05pm — 1:25pm 1:25pm — 1:45pm	The Impact of the Kidney on Cardiovascular Complications in Diabetes Q+A Panel Discussion	Mark E. Cooper, AO, PhD	
SESSION 14	INTERPRETING CVOT — IMPLICATIONS FOR PRACTICE Chairs: Javed Butler, MD • Vivian A. Fonseca, MD • Yehuda Handelsman, MD		

## DEBATE/PANEL: WHICH MEDICATION IS PREFERRED FOR A PATIENT WITH DM AND ESTABLISHED CVD?

1:45pm — 1:50pm	Case Presentation	Yehuda Handelsman, MD
1:50pm — 2:00pm	GLP1-ra	Mansoor Husain, MD
2:00pm — 2:10pm	SGLT2i	Daniel Einhorn, MD
2:10pm — 2:20pm	EPA	Michael Miller, MD
2:20pm — 2:30pm	PCSK9i	Christie M. Ballantyne, MD
2:30pm — 2:50pm	Q+A Panel Discussion	
2:50pm — 3:00pm	Post CME Questions	

3:00PM ADJOURN



## Yehuda Handelsman, MD FACP, FNLA, FASPC, MACE

Chair & Program Director
3rd HiD & 17th WCIRDC
Medical Director & Principal Investigator
Metabolic Institute of America
Chair & Founder
International Committee for
Insulin Resistance
Chair & Founder, International Lipid Forum
Tarzana, California



## Mikhail N. Kosiborod MD FACC, FAHA

Chair & Program Director 3rd HiD Professor of Medicine Saint Luke's Mid America Heart Institute University of Missouri-Kansas City School of Medicine Kansas City, Missouri



## George L. Bakris, MD, MA Hon. DSc, FASN, FAHA

Professor of Medicine (tenured) Director, AHA Comprehensive Hypertension Center The University of Chicago Medicine Chicago, Illinois



## Christie M. Ballantyne, MD FACP, FACC

Chief, Sections of Cardiology and Cardiovascular Research Professor and Vice Chair of Research Department of Medicine Director, Center for Cardiometabolic Disease Prevention Baylor College of Medicine Houston, Texas



## Deepak L. Bhatt, MD, MPH FACC, FAHA, FSCAI, FESC

Executive Director of Interventional Cardiovascular Programs Brigham and Women's Hospital Heart & Vascular Center Professor of Medicine Harvard Medical School Boston, Massachusetts



### Zachary T. Bloomgarden, MD MACE

Editor, the Journal of Diabetes www.jdiabetes.com Clinical Professor Department of Medicine Icahn School of Medicine at Mount Sinai New York, New York



## Biykem Bozkurt, MD, PhD FHFSA, FACC, FAHA

Professor of Medicine
The Mary and Gordon Cain and
W.A. "Tex" and Deborah Moncrief, Jr.
Chair
Medical Care Line Executive, DeBakey
VA Medical Center
Director, Winters Center for
Heart Failure Research
Associate Director, Cardiovascular
Research Institute
Vice-Chair of Medicine
Baylor College of Medicine
Houston, Texas



## Eliot A. Brinton, MD FAHA, FNLA

President, Utah Lipid Center Salt Lake City, Utah



## Matthew J. Budoff, MD FACC, FAHA

Professor of Medicine
UCLA School of Medicine
Endowed Chair of Preventive Cardiology
Harbor-UCLA Medical Center
Division of Cardiology
Program Director
Director of Cardiac CT
Los Angeles, California



#### Javed Butler, MD, MPH, MBA

Professor and Chairman Department of Medicine University of Mississippi Medical Center Oxford, Mississippi



### Juliana CN Chan, MD MBChB, FRCP

Professor of Medicine and Therapeutics Director, Hong Kong Institute of Diabetes and Obesity Chinese University of Hong Kong Prince of Wales Hospital Hong Kong, China



## Robert J. Chilton, DO FACC, FAHA

Professor of Medicine Department of Medicine Division of Cardiology The University of Texas Health Science Center San Antonio, Texas



## Mark E. Cooper, AO, MB BS PhD, FRACP, FAHMS

Head, Department of Diabetes Central Clinical School Monash University Senior Endocrinologist Alfred Health Clinic Melbourne, Australia



### Maria Rosa Costanzo, MD FAHA, FACC, FESC

Medical Director, Heart Failure Research Advocate Heart Institute Medical Director, Edward Hospital Center for Advanced Heart Failure Naperville, Illinois



## Michael H. Davidson, MD FACC, FACP, FNLA

Professor, Director of the Lipid Clinic The University of Chicago Pritzker School of Medicine Chicago, Illinois



## Ralph A. DeFronzo, MD

Professor of Medicine Chief, Diabetes Division University of Texas Health Science Center at San Antonio (UTHSCSA) Deputy Director, Texas Diabetes Institute San Antonio, Texas



#### Stefano Del Prato, MD

Professor of Endocrinology and Metabolism Chief of the Section of Diabetes University of Pisa, School of Medicine Pisa, Italy



## David H. Fitchett, MD MRCP, FRCP, FACC, FESC

Associate Professor of Medicine University of Toronto Staff Cardiologist at St Michael's Hospital Toronto, Canada





## Robert H. Eckel, MD

Professor of Medicine
Division of Endocrinology
Metabolism and Diabetes
Division of Cardiology
Professor of Physiology and Biophysics
Charles A. Boettcher II
Chair in Atherosclerosis
Vice Chancellor for Research (VCR), Interim
University of Colorado Denver Anschutz
Medical Campus
Director Lipid Clinic
University of Colorado Hospital
Denver, Colorado



## Daniel Einhorn, MD FAC, FACE

Chief, Diabetes and Endocrine Associates Medical Director, Scripps Whittier Diabetes Institute Clinical Professor UCSD School of Medicine La Jolla, California



## Michael E. Farkouh, MD FRCPC, MSc. FACC, FAHA

Professor and Vice-Chair, Research
Department of Medicine,
Peter Munk Chair in Multinational
Clinical Trials
Peter Munk Cardiac Centre
Director of the Heart & Stroke,
Richard Lewar Centre of Excellence in
CV Research.
University of Toronto
Toronto Ontario, Canada



## Sergio Fazio, MD, PhD

The William and Sonja Connor Chair of Preventive Cardiology Professor of Medicine and Physiology & Pharmacology Director, Center for Preventive Cardiology Knight Cardiovascular Institute Oregon Health & Science University Portland, Oregon



### Vivian A. Fonseca, MD, FRCP

Professor of Medicine and Pharmacology Assistant Dean for Clinical Research Tullis Tulane Alumni Chair in Diabetes Chief, Section of Endocrinology Tulane University Health Sciences Center New Orleans, Louisiana



## Valentin Fuster, MD, PhD

Director, Mount Sinai Heart Physician-in-Chief, Mount Sinai Hospital Mount Sinai Health System New York, New York



## Alan J. Garber, MD, PhD MACE

Professor of Medicine Biochemistry and Molecular Biology, and Molecular & Cellular Biology Baylor College of Medicine Houston, Texas



## Robert P. Giugliano, MD, SM

Senior Investigator, TIMI Study Group Physician, Cardiovascular Medicine Brigham and Women's Hospital Associate Professor of Medicine Harvard Medical School Boston, Massachusetts



## Shinichi Goto, MD, PhD

Assistant Professor Department of Cardiology Keio University School of Medicine Tokyo, Japan



#### Antonio Gotto Jr, MD, DPhil

Professor of Medicine Provost for Medical Affairs Emeritus & Dean Emeritus Weill Cornell Medicine New York, New York



### Peter J. Grant, MD FRCP, FMedSci

Professor of Medicine and Consultant Physician, University of Leeds/Leeds Teaching Hospitals NHS Trust, Leeds Institute of Cardiovascular and Metabolic Medicine, LIGHT Laboratories Leeds, United Kingdom



## George Grunberger, MD FACP, FACE

Chairman, Grunberger Diabetes Institute
Clinical Professor, Internal Medicine and
Molecular Medicine & Genetics
Wayne State University
School of Medicine
Professor, Internal Medicine
Oakland University William Beaumont
School of Medicine
Visiting Professor, Internal Medicine
First Faculty of Medicine, Charles
University, Prague, Czech Republic
Past President, AACE
Bloomfield Hills, Michigan



### Martha Gulati, MD, MS FACC, FAHA, FASPC

Chief of Cardiology, University of Arizona College of Medicine- Phoenix Editor-in-Chief, CardioSmart for The American College of Cardiology Phoenix, Arizona



#### Eric Hernandez-Triana, MD

Professor Titular Universidad del Rosario, Bogota Scientific Director Endocare Research Institute Bogotá, Colombia



## Mansoor Husain, MD BSc, FRCPC

Executive Director, Ted Rogers Centre for Heart Research
Director, Toronto General Hospital
Research Institute
Professor, Department of Medicine
University of Toronto
Senior Scientist, Toronto General
Hospital Research Institute
University Health Network
Toronto, Canada



## Silvio E. Inzucchi, MD

Professor of Medicine Yale School of Medicine Clinical Chief, Endocrinology and Medical Director Yale Diabetes Center Yale-New Haven Hospital New Haven, Connecticut



Paul S. Jellinger, MD, MACE
Professor of Clinical Medicine
Voluntary Faculty
University of Miami
Miller School of Medicine
The Center for Diabetes &
Endocrine Care
Past President, AACE & ACE
Hollywood, Florida



Samuel Klein, MD

William H. Danforth Professor of Medicine and Nutritional Science Director, Center for Human Nutrition Chief, Division of Geriatrics and Nutritional Science Washington University School of Medicine St. Louis, Missouri



Norman E. Lepor, MD FACC, FAHA, FSCAI

Attending Physician
Cedars-Sinai Heart Institute
Clinical Professor of Medicine
Geffen School of Medicine-UCLA
Co-founder of Imaging and Director of
Medical Discovery
Westside Medical Imaging/Westside
Medical Associates of Los Angeles
Los Angeles, California



Cecilia C. Low Wang, MD FACP

Associate Professor of Medicine
Director, Glucose Management Team,
University of Colorado Hospital
Director, Housestaff and Student
Education, Division of Endocrinology,
Metabolism and Diabetes, Department
of Medicine, University of Colorado
Anschutz Medical Campus
School of Medicine
Lead Clinician-Scientist,
CPC Clinical Research
Denver, Colorado



Christos S. Mantzoros, MD DSc, PhD h.c. mult.

Professor of Medicine,
Harvard Medical School and Boston
University School of Medicine
Chief of Endocrinology,
Diabetes and Metabolism
Boston VA Healthcare System
Director of Human Nutrition
Beth Israel Deaconess Medical Center
Editor-in-Chief, Metabolism
Clinical & Experimental
Boston, Massachusetts



Peter A. McCullough, MD MPH, FACC, FACP, FCCP FAHA, FNKF, FCRSA

Vice Chief of Medicine Baylor University Medical Center Dallas, Texas



Darren K. McGuire, MD MHSc, FAHA, FACC, FESC

Professor of Medicine
Dallas Heart Ball Chair for Research on
Heart Disease in Women,
Distinguished Teaching Professor of
Internal Medicine
University of Texas Southwestern
Medical Center
Director, Parkland Hospital and Health
System Cardiology Clinics
Deputy Editor, Circulation
Dallas, Texas



## Christian W. Mende, MD FACP, FACN, FASN, FASH, FAHA

Clinical Professor of Medicine University of California San Diego La Jolla, California



## Robert J. Mentz, MD FACC, FAHA, FHFSA

Associate Professor of Medicine
Director, Duke Cooperative
Cardiovascular Society
Associate Program Director, Duke
Cardiovascular Disease Fellowship
Duke University Medical Center and
Duke Clinical Research Institute
Durham, North Carolina



## Michael Miller, MD ACC, FAHA, FNLA, FASPC

Professor of Cardiovascular Medicine Epidemiology & Public Health University of Maryland School of Medicine Baltimore, Maryland



### Michael Nauck, MD

Head of Clinical Research Division of Diabetology Medical Department St. Josef-Hospital (Ruhr-Universität Bochum) Bochum, Germany



## Richard E. Pratley, MD

Samuel E. Crockett Chair in Diabetes Research Medical Director AdventHealth Diabetes Institute Senior Investigator and Diabetes Program Lead, Translational Research Institute for Metabolism and Diabetes AdventHealth Orlando Orlando, Florida



## Kausik Ray, MD, MBChB MPhil (Cantab), FRCP (Lon), FRCP (Ed), FACC, FESC, FAHA

Professor of Public Heath
Consultant Cardiologist
Deputy Director of The Imperial Clinical
Trials Unit/ Head of Commercial Trials
Department of Public Health and
Primary Care
School of Public Health
Imperial College
London, United Kingdom



## Peter Reaven, MD

Professor of Clinical Medicine University of Arizona Director, Diabetes Program Carl T. Hayden VAMC (111E) Adjunct Research Professor Arizona State University Phoenix, Arizona





Jane E.B. Reusch. MD

Professor of Medicine, Bioengineering and Biochemistry
Endocrinology, Metabolism and Diabetes Associate Director, Center for Women's Health Research
University of Colorado
Anschutz Medical Campus SOM
VA Staff Physician and Merit Investigator CCTSI-VA Liaison
American Diabetes Association, 2018
President for Medicine and Science
Denver. Colorado



## Paulo Cury Rezende, MD, PhD

Collaborating Professor
University of São Paulo Medical School
Assistant-Doctor and Researcher of the
MASS Research Group
(Heart Institute — University of
São Paulo Medical School)
São Paulo, Brazil



### Robert S. Rosenson, MD

Professor of Medicine (Cardiology)
Icahn School of Medicine at Mount Sinai
Director of Cardiometabolics Unit
Zena and Michael A. Wiener
Cardiovascular Institute
Marie-Josee and Henry R. Kravis Center
for Cardiovascular Health
Mount Sinai Hospital
New York, New York



### Marc Ruel, MD MPH, FRCSC, FCCS, FAHA

M. Pitfield Chair & Head, Division of Cardiac Surgery University of Ottawa Heart Institute University of Ottawa Professor, Departments of Surgery & Cellular and Molecular Medicine University of Ottawa Ottawa, Ontario, Canada



## Elizabeth Selvin, PhD MPH, FAHA

Professor of Epidemiology & Medicine Director, Cardiovascular and Clinical Epidemiology Department of Epidemiology Welch Center for Prevention Epidemiology and Clinical Research Johns Hopkins Bloomberg School of Public Health Baltimore, Maryland



## Mandeep S. Sidhu, MD

Associate Professor of Medicine
Albany Medical College
Division of Cardiology
Albany Medical Center
Assistant Dean for Medical Education
and Student Research
Albany Medical College
Adjunct Professor of
Health Care Management
Clarkson University, Schenectady, NY
Albany, New York



## Michael Snyder, PhD

Professor and Chair of Genetics Director, Center for Genomics and Personalized Medicine Stanford University School of Medicine Stanford, California



## Laurence Sperling, MD FACC, FACP, FAHA, FASPC

Katz Professor in Preventive Cardiology Director of the Emory Heart Disease Prevention Center Professor of Global Health Hubert Department of Global Health Rollins School of Public Health at Emory University Atlanta, Georgia



## Pam R. Taub, MD, FACC

Director of Step Family Foundation Cardiovascular Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Division of Cardiovascular Medicine San Diego, California



## Peter P. Toth, MD, PhD FESC, FACC

Director of Preventative Cardiology
CGH Medical Center Sterling, Illinois
Professor of Clinical Family and
Community Medicine
University of Illinois School of Medicine
Peoria, Illinois
Professor of Clinical Medicine
Michigan State University
College of Osteopathic Medicine
East Lansing, Michigan
Adjunct Associate Professor of Medicine
Division of Cardiology
Johns Hopkins University
School of Medicine
Baltimore, Maryland



### Muthiah Vaduganathan, MD MPH

Cardiology Faculty Brigham and Women's Hospital Boston, Massachusetts




## Subodh Verma, MD, PhD FRCSC, FAHA

Cardiac Surgeon, St. Michael's Hospital Scientist, Keenan Research Centre for Biomedical Science and Li Ka Shing Knowledge Institute of St. Michael's Hospital Professor of Surgery and Pharmacology & Toxicology University of Toronto Canada Research Chair in Cardiovascular Surgery Toronto, Ontario, Canada



### Matthew R. Weir, MD

Professor and Chief Division of Nephrology Department of Medicine University of Maryland School of Medicine Baltimore, Maryland



Or email: info@tmioa.com

To register by phone: (818) 342-1889

Registration Fee: \$350 (special ends on June 30th)

CANCELLATION POLICY: A full refund will be given if written notice of cancellation is received by Friday, May 12, 2019. A \$75 cancellation fee will be charged for cancellation between May 13, 2019 and June 14, 2019. After June 14, 2019 there will be NO REFUND. Cancellations must be submitted via e-mail to info@tmioa.com or by phone at 818-342-1889.

#### **ACCREDITATION INFORMATION**

You can earn up to 24.75 credits

#### **CME ACCREDITATION**

This activity was planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of PESI Inc. and the Metabolic Endocrine Education Foundation (MEEF). PESI Inc. is accredited by the ACCME to provide continuing medical education for physicians.

## **AMA PRA Designation Statement**

The PESI Inc. designated this live activity for a maximum of 24.75 AMA PRA Category 1 Credit(s) $^{\text{TM}}$ . Physicians should only claim credit commensurate with the extent of their participation in the activity

#### **International CME**

International Physicians are formally eligible for AMA PRA Category 1 Credit $^{TM}$ .

#### **Physician Assistants**

AAPA accepts Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit  $^{TM}$  for the PRA from organizations accredited by ACCME.

#### Nurses

For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

#### **CA Nurses**

Aspen CME Services is approved by the California Board of Registered Nursing, provider number CEP14739, designated the 3<sup>rd</sup> HiD for approximately 24.75 contact hours.

#### **Pharmacists**

For the purpose of recertification, the American Council of Pharmacy Education accepts AMA PRA Category 1 Credit<sup>™</sup> issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

#### CDE

The National Certification Board for Diabetes Educators recognizes courses sponsored by PESI Inc. as approved ACCME provider. This course qualifies for 24.75 continuing education hours.

#### **REGISTERED DIETICIANS**

For the purpose of recertification the Commission on Dietetic Registration recognizes courses accredited with AMA PRA Category 1 Credit<sup>TM</sup>.

#### **Satisfactory Completion for credits:**

All attendees must have completed and turned in a course attendance/evaluation form prior to leaving the conference. Each session claimed for credit must be attended in its entirety.

#### **ACCOMMODATIONS**

The 3<sup>rd</sup> Annual Heart in Diabetes (HiD) CME conference will be held at the Loews Philadelphia Hotel 1200 Market St, Philadelphia, PA 19107 USA (215) 627-1200 https://www.loewshotels.com/philadelphia-hotel

To reserve a room at the special rate of \$169 single/double a night for conference participants and their guests please go online: https://www.heartindiabetes.com/accomodations OR call (215) 627-1200 to make your individual reservation within the room block by providing the following information:

**Event Name:** 3<sup>rd</sup> Annual Congress on Heart in Diabetes (HiD)

Reservation ID: MIA11J

Group rate is available until June 12, 2019 Subject to Availability

Rooms will be available on a first-come basis, and will be available until all are filled. Group room rates will be available three (3) days prior to and three (3) days after the event date. If you need special accommodations or if you have any questions about access to any of our activities, please contact the meeting organizers at 818 342 1889 or info@tmioa.com

The HiD Scientific Committee Gratefully Acknowledges the Corporate Support of Sapphire Level: AMGEN • SANOFI • JANSSEN

## The Metabolic Institute of America (TMIOA)

18372 Clark Street #212, Tarzana, CA 91356



NONPROFIT
ORG
US POSTAGE PAID
VAN NUYS CA
PERMIT # 659

July 12-14, 2019 · Loews Philadelphia Hotel · 1200 Market St. Philadelphia, PA 19107

# USE COUPON CODE "BROCHURE" AND SAVE 10% ON REGISTRATION ATTENDANCE IS LIMITED!

Registration FEE until June 30th: \$350 Onsite: \$550

Register online: www.heartindiabetes.com/registration Or email us: info@tmioa.com To register by phone: (818) 342-1889

Cancellation Policy: A full refund will be given if written notice of cancellation is received by May 19, 2019. A \$75 cancellation fee will be charged for cancellation between May 20, 2019 and June 14, 2019. After June 14, 2019 there will be NO REFUND. Cancellations must be submitted via e-mail to info@tmioa.com or by phone at 818-342-1889.

#### **ENDORSING ORGANIZATIONS:**

- American Association of Clinical Endocrinologists (AACE)
- American Society of Endocrine Physician Assistants (ASEPA)
- California Chapter of the American College of Cardiology (CAACC)
- FH Foundation
- National Lipid Association (NLA)
- Pediatric Endocrine Society
- Society for Vascular Surgery

#### **MEDIA PARTNERS:**

- Bentham Science
- Cardiology Advisor
- Cardiology Today (Healio)
- Cardiovascular, Endocrinology & Metabolism
- Clinical Cardiology (Wiley)
- Conference Locate
- Diabetes in Control
- Diabetes Research and Clinical Practice (Elsevier)
- Diabetes & Vascular Disease Research (Sage)
- Endocrine Web
- Endocrine Today (Healio)

- International Journal of Cardiovascular Research (SciTechnol)
- Journal of Diabetes
- JSciMed Central
- Metabolism (Elsevier)
- MIMS
- PharmaVoice
- Physician's Weekly
- Vessel Plus
- VuMedi

For additional information on

REGISTRATION • ACCOMMODATIONS • SUPPORT • EXHIBITS (818) 342-1889 info@tmioa.com | www.heartindiabetes.com